Patient Perspective on Cross-Linking

Learn more about the importance of early diagnosis and treatment from a keratoconus patient and her treating physician.

A General Overview

Corneal cross-linking is a minimally invasive outpatient procedure that combines the use of Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution), Photrexa® (riboflavin 5’-phosphate ophthalmic solution) and the KXL® system for the treatment of progressive keratoconus.

Corneal Cross-Linking:
  • Creates new corneal collagen cross-links
  • Results in a shortening and thickening of the collagen fibrils
  • Leads to the stiffening of the cornea

Top Questions to Ask Your Eye Doctor Download PDF

FDA Approval

The first and only therapeutic products for corneal cross-linking which have been FDA approved to treat progressive keratoconus.

In April 2016, the FDA approved Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5’-phosphate ophthalmic solution) and the KXL® System for corneal cross-linking, a minimally invasive outpatient procedure that combines the use of Vitamin B2 eye drops and ultra-violet (UV) light.

The approval of Photrexa Viscous, Photrexa and the KXL System offers an effective treatment for patients who, until recently, had no therapeutic options to limit the progression of this sight-threatening disease.

Cross-Linking

Learn more about this outpatient procedure

View our Living with Keratoconus Patient Brochure.

Patient FAQs

Discover answers to the most common questions surrounding cross-linking

Visit the Patient FAQ Section to learn more.

It is estimated that...

1 Out of Every 2,000

persons in the general population have Keratoconus1

You can find more information from the National Keratoconus Foundation.

1. Kennedy R. H., Bourne W. M., Dyer J. A. A 48-year clinical and epidemiologic study of keratoconus. The American Journal of Ophthalmology. 1986;101(3):267–273. doi: 10.1016/0002-9394(86)90817-2.

Corneal cross-linking provides patients a much-needed option to treat this debilitating disease. Patients suffering from progressive keratoconus can now receive a therapeutic treatment that has been rigorously tested and approved."

Mary Prudden, Executive Director for the National Keratoconus Foundation

What are Patients Saying? View Stories

Learn More Through Our Facebook Page

2 days ago

Living with KC

Who else can relate?! #LivingWithKC #glassesproblems ... See MoreSee Less

View on Facebook

3 days ago

Living with KC

"I am extremely grateful to have had the opportunity to continue my education on time and being able to look towards my future without fear." - Gage on #LivingWithKC and being a college student. www.livingwithkeratoconus.com/kc-journeys/keratoconus-journey-gage/ ... See MoreSee Less

View on Facebook

Learn More Through Our Twitter Page

Growing up with vision issues, Gage assumed everyone saw the world like he did. It wasn't until the summer before his freshman year of college that he realized something was wrong. Read Gage's #KCJournye today! https://t.co/9UQnxCd8Ab

"As a result of cross-linking, it helped halt the progression of the disease. But it also helped me to be fit for better contacts." - Shanice Cole, tight end for the Black Widows @rvaBlackWidows #LivingWithKC https://t.co/gCoob7a67x

"I am extremely grateful to have had the opportunity to continue my education on time and being able to look towards my future without fear." - Gage on #LivingWithKC and being a college student. https://t.co/9UQnxCd8Ab

Insurance update - Emblem Health is now covering #crosslinking! https://t.co/B5stNJdheA

Load More...

Learn More Through Our Instagram

MA-00687B